Volume 8, Issue 6 (November 2006) 8, 685–692; 10.1111/j.1745-7262.2006.00213.x
Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study
Wai Chun Andrew Yip, Han-Sun Chiang, Jesus Benjamin Mendoza, Hui-Meng Tan, Man-Kay Li, Wei Christine Wang and Vladimir Kopernicky
1.Department of Surgery, Kwong Wah Hospital, Hong Kong, China
2.College of Medicine, Fu Jen Catholic University, Taipei 24205, Taiwan, China
3.Department of Urology, National Kidney and Transplant Institute, Quezon City 1100, the Philippines
4.Department of Urology, Subang Jaya Medical Centre, Selangor Darul Ehsan 47500, Malaysia
5.Department of Urology, National University Hospital, 119074, Singapore
6.Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
7.Lilly Area Medical Center, Vienna 1030, Austria
Correspondence: Dr Wai Chun Andrew Yip, Department of Surgery, Kwong Wah Hospital, 25 Waterloo Road, Kowloon, Hong Kong, China. Fax: +852-2781-5264. E-mail: email@example.com
Received 8 March 2006; Accepted 15 June 2006
Aim: To assess the efficacy and safety of tadalafil in comparison to a placebo, when taken on demand for 12 weeks by East/Southeast Asian men with erectile dysfunction (ED).
Methods: This multicenter, randomized, double-blind, parallel group, placebo-controlled study was conducted at 17 centers across East and Southeast Asia between August 2002 and February 2003. Men more than 18 years of age with mild to severe ED of various etiologies were randomized to receive a placebo or 20 mg of tadalafil taken as needed (maximum once daily). Efficacy assessments included the International Index of Erectile Function, the Sexual Encounter Profile diary and Global Assessment Questions.
Results: Tadalafil significantly improved erectile function as compared to the placebo (P < 0.001). At the endpoint, the patients receiving 20 mg of tadalafil reported a greater mean per patient percentage of successful intercourse attempts (Sexual Encounter Profile question 3: 70.9% compared to 33.5% in the placebo) and a greater proportion of improved erections (Global Assessment Question: 86.2% compared to 30.1%). Most ( 3%) treatment emergent adverse events were mild or moderate. The most common treatment emergent adverse events were headache, back pain, dizziness and dyspepsia.
Conclusion: Tadalafil was an effective and well-tolerated treatment for ED in East and Southeast Asian men.
Keywords: tadalafil, phosphodiesterase type 5 inhibitor, erectile dysfunction, efficacy, safety, Asian
Full Text |